

- Pneumocystis pneumonia* (PCP)
 in cancer patient, 485, 489, 489t
 clinical features of, 1359, 1360f
 diagnosis of, 489, 1359–1360, 1360f
 ectopic ACTH production and, 611–612
 epidemiology of, 1358
 in HIV infection, 1250, 1251t, 1253, 1358, 1361
 pathogenesis of, 1358–1359, 1359f
 prevention of, 492
 prognosis of, 1360–1361
 prophylaxis for, 1361–1362, 1362t
 in HIV infection, 1251t
 pentamidine, 667
 trimethoprim-sulfamethoxazole, 139e-4t, 423
 sputum collection in, 1667
 in transplant recipient
 after HSCT, 921, 1358
 after solid organ transplant, 924t, 926, 927, 1358
 prophylaxis for, 139e-4, 139e-4t, 1361–1362, 1830
 treatment of, 1361, 1361t
 Pneumolysin, 947, 947f
 Pneumomediastinum, 1720
 Pneumonectomy, for lung cancer, 514, 516–517
 Pneumonia, **803**
 abdominal pain in, 105, 106t
 atypical, 804
 bacterial. *See also* Pneumonia, community-acquired
 actinomycotic, 1088
 after influenza, 958, 1212
 case-fatality ratios for, 949–950
 clinical features of, 950–951, 968
 complications of, 951, 968
 diagnosis of, 308e-10f, 951, 951f
 differential diagnosis of, 951
 E. coli, 1028
 F. tularensis, 1068
 in granulomatosis with polyangiitis, 386e-2f
 H. influenzae, 1011
 in HIV infection, 1250. *See also*
 Pneumocystis pneumonia (PCP)
 incidence pre- and postvaccine, U.S., 785t, 949f, 953, 953f
 K. pneumoniae, 1032
 Legionella. *See Legionella* spp. infections
 M. catarrhalis, 1013
 Nocardia, 308e-6f, 1084–1086, 1085f, 1086f
 nontyphoidal *Salmonella*, 1054
 P. aeruginosa, 1044–1045, 1045t, 1047
 parapneumonic effusion in, 1717
 T. whipplei, 1092
 treatment of, 952–953, 965t
 in burn patient, 166e-2
 C. pneumoniae, 1173–1174
 C. psittaci, 1173
 in cancer patient, 488–489, 489t, 1797
 chest pain in, 96t, 98
 Coccidioides, 1335
 community-acquired
 clinical features of, 805
 complications of, 808–809
 diagnosis of, 805–806
 epidemiology of, 805, 805t
 etiology of, 804–805, 804t, 806, 1015
 follow-up, 809
 PPIs and, 1921
 prevention of, 809
 prognosis of, 809
 risk factors for, 805, 805t
 severity indicators, 806–807, 807t
 treatment of
 antibiotic resistance in, 807
 empirical antibiotics, 767t, 807–808, 808t
 failure to respond to, 808
 general considerations, 808–809
 racial/ethnic disparities in, 16e-1, 16e-2f
 site of care, 806–807
 cryptogenic organizing, 1712–1713
 cyanosis in, 249
 deaths from, 6e-1t, 56t, 804
 definition of, 803
 eosinophilic. *See* Pulmonary infiltrates with eosinophilia
 health care–associated. *See also* Ventilator-associated pneumonia (VAP)
 conditions associated with, 803, 803t
 diagnosis of, 958
 prevention of, 914–915
 risk factors for, 809, 914
 treatment of, 767t, 914
 hemoptysis in, 245
 hospital-acquired, 767t, 813, 1015, 1020
 incidence of, 804
 infant (*C. trachomatis*), 1170t, 1171
 interstitial. *See* Interstitial pneumonia
 M. pneumoniae, 1163
 mixed viral and bacterial, 1212
 necrotizing, 812
 pathology of, 804
 pathophysiology of, 306e-3, 804
 Pneumocystis. *See Pneumocystis pneumonia* (PCP)
 Q fever, 1161
 R. equi, 981
 in transplant recipient, 923, 925–926
 typical, 804
 ventilator-associated. *See* Ventilator-associated pneumonia (VAP)
 viral
 adenovirus, 1208
 CMV, 1192
 enterovirus, 1293
 HMPV, 1207
 HRSV, 1206
 parainfluenza, 1207
 primary influenza, 1212
 varicella, 1184
 Pneumonia Severity Index (PSI), 806
 Pneumonic plague, 261e-3, 261e-5t, 1072, 1073f.
 See also Plague
 Pneumonitis
 aspiration, anaerobic, 1098
 in cancer patient, 489, 489t, 621–622, 1797
 deaths from, by sex, 6e-1t
 giant-cell, 1297, 1298
 HSV, 1179–1180
 hypersensitivity. *See* Hypersensitivity pneumonitis
 lymphocytic interstitial, 1716
 necrotizing, anaerobic, 1098
 radiation-induced, 1797
 VZV, 1183
 Pneumoperitoneum, 847, 847f
 Pneumothorax
 chest pain in, 96t, 98
 as contraindication to hyperbaric oxygen therapy, 477e-2
 imaging of, 308e-13–14f
 in mechanically ventilated patient, 1743
 spontaneous, 98, 1719
 tension, 98, 1719, 1750
 traumatic, 1719
 PNKD (paroxysmal nonkinesigenic dyskinesia), 2625
 Podagra, with gouty inflammation, 436e-2f
 Podophyllotoxin
 adverse effects of, 2687t
 for warts, 351, 1201, 1201t
 POEMS syndrome (Crow-Fukase syndrome), **718**
 clinical features of, 361, 715t, 718, 2348, 2700
 diagnosis of, 715t
 paraneoplastic, 619
 pathogenesis of, 718, 2348
 treatment of, 718, 2348
 Poikilocytes, 81e-1, 627
 Poikilocytosis, 81e-1, 394, 413, 637, 657
 Poikiloderma, 340t, 356t, 357, 374–375
 Poikilothermia, 478e-3
 Point mutation, 101e-2–3, 101e-4, 432–433, 433f
 Poisoning/drug overdose. *See also specific substances*
 epidemiology of, 473e-1
 history in, 473e-1
 hypothermia in, 478e-1
 laboratory evaluation in, 473e-3–4, 2764–2766t
 pattern recognition in, 473e-1, 473e-2t
 phases of, 473e-4
 physical examination in, 473e-1
 severity assessment in, 473e-1–3, 473e-2t
 treatment of
 antidote administration, 473e-7
 cardiovascular therapy, 473e-5
 CNS therapy, 473e-5–6
 decontamination at other sites, 473e-6–7
 enhancement of poison elimination, 473e-7
 gastrointestinal decontamination, 473e-6
 general principles, 473e-4–5, 473e-4t
 prevention of reexposure, 473e-7
 respiratory care, 473e-5
 supportive care, 473e-5
 Poison ivy, 345
 Poison oak, 345
 Poison sumac, 345
 Poisson distribution, 87e-1, 87e-2f
 Polar bear bite-wound, 167e-1
 Polarized cells, 332e-3
pol gene, 225e-1, 225e-2, 225e-3f, 1218, 1219f
POLG gene, 462e-16
 Poliomyelitis. *See* Poliovirus infection
 Poliovirus, 214e-6, 1289–1290
 Poliovirus infection
 clinical features of, 1290–1291
 elimination and eradication of, 785
 epidemiology of, 1290
 global considerations in, 786, 896, 1294, 1294t
 incidence pre- and postvaccine, U.S., 785t
 paralytic poliomyelitis, 1290
 pathogenesis of, 1290
 postpolio syndrome, 1291, 2633
 prevention and eradication of, 1294, 1294t
 vaccine-associated, 1291
 weakness in, 156
 Poliovirus vaccine
 effectiveness of, 1294
 poliomyelitis associated with, 1291, 1294
 recommended administration of
 in adults, 1295t
 in cancer patient, 485t
 in transplant recipient, 929, 929t
 in travelers, 794
 types of, 1294
 Polonium-210 exposure, 263e-3t
 POLST (Physician Orders for Life-Sustaining Treatment), 58–59
 Polyangiitis
 with granulomatosis. *See* Granulomatosis with polyangiitis (Wegener's)
 microscopic. *See* Microscopic polyangiitis
 Polyangiitis overlap syndromes, 2193
 Polyarteritis nodosa, **2187**
 clinical features of, 2187, 2187t
 definition of, 2187
 diagnosis of, 386e-3f, 386e-4f, 386e-6f, 2188–2189
 incidence and prevalence of, 2187
 neuropathy in, 2700
 pathology and pathogenesis of, 2180, 2187
 skin manifestations of, 364t, 366, 368–369
 treatment of, 2188
 Polyarthropathy syndrome, 1196, 1196t
 Polychondritis, relapsing. *See* Relapsing polychondritis
 Polychromasia, 394, 729
 Polychromatophilia, 81e-1, 81e-3f
 Polychromotropism, 575
 Polycomb family, 89e-4
 Polycyclic hydrocarbons, 119e-1, 477t
 Polycystic kidney disease
 autosomal dominant, **1850**
 clinical features of, 1621t, 1851–1852, 1852f
 diagnosis of, 1622, 1852–1853
 early interventions for, 450t
 genetic considerations in, 436t, 1621t, 1850–1851, 1850t
 genetic testing for, 450t